GVHD is a significant cause of morbidity and mortality following allogeneic peripheral blood stem cell transplantation (AlloPBSC). CD34
In recent years, peripheral blood has been increasingly replacing bone marrow as a source of stem cells for allogeneic transplantation. Advantages of allogeneic peripheral blood stem cell (AlloPBSC) include avoidance of anesthesia and the potential morbidity associated with marrow collection. For the recipient, advantages include rapid engraftment, accelerated immunologic recovery and possible enhanced anti-neoplastic effects. Compared with bone marrow, alloPBSC transplantation does not appear to increase the risk of acute GVHD. However, the risk of chronic GVHD may be increased, possibly as a result of the approximately one log increase in T cells present in PBSC products. [1] [2] [3] When T cell depletion equals or exceeds 2 logs (1 ϫ 10 5 T cells/kg), the risk of GVHD following alloBMT is significantly reduced. 3 Although, the level of T cell depletion required to reduce GVHD in the setting of alloPBSC is not known, enrichment for CD34 ϩ cells could reduce GVHD by negative selection of T cells. BDS 60 (Dendreon Corporation, Seattle, WA, USA) is an isotonic colloidal silica solution in a physiological buffer (pH 7.4). The density of the solution is adjusted to deplete 70% of the total nucleated cells (TNC) but recover 80% of CD34 ϩ cells during centrifugation of mobilized PBSC on the density gradient solution. 4 T lymphocytes are depleted by approximately one log. BDS 60 has been evaluated in autologous transplant patients and has recently been approved for marketing by the FDA for autologous transplants as the 'DACS SC Kit'. 5 Processing alloPBSC using BDS 60 could augment the effectiveness of other techniques for T depletion by reducing the CD3 ϩ cell content of the starting product. This could be of particular importance in the setting of allogeneic PBSC since Ͼ3 log T cell depletion may be needed to reduce the risk of GVHD. In the current trial we set out to determine the feasibility of processing G-CSF-mobilized alloPBSC using this device. We encountered an unexpectedly high rate of GVHD which led to a detailed analysis of the cellular content of the processed products. We now report our observations.
Patients and methods

Patients/donors
Eligibility criteria included: age Ͼ10 years; hematological malignancies including (1) acute leukemia relapsed, refractory or in first CR if preceding MDS, secondary to prior treatment or high-risk cytogenetics, (2) CML in stable, accelerated or 2nd chronic phase, (3) myelodysplasia with transfusion dependence or severe neutropenia, (4) relapsed or refractory lymphoma, (5) multiple myeloma; ECOG performance status 0-2; and no severe medical problems. Donors were HLA-identical siblings with no significant medical problems. HLA typing was performed using standard serologic techniques for the HLA A and B loci with molecular typing for the HLA-DRB1 locus. The protocol was approved by the institutional review board of Washington University. All patients and donors signed informed consent forms.
Conditioning regimen and transplant procedure
Ten patients received 1225 cGy total body irradiation in seven fractions, etoposide 30 mg/kg and cyclophosphamide 120 mg/kg for conditioning. One was conditioned with Bu/Cy2. Details regarding these conditioning regimens have been previously described. 6 GVHD prophylaxis consisted of cyclosporin A (CsA) 3 mg/kg/day continuous intravenous infusion (i.v.) starting on day Ϫ1. Trough whole blood CsA levels were checked twice a week and maintained at 250-500 mg/ml. CsA was changed to p.o. when oral intake was adequate and continued at full doses for у3 months post transplant. Thereafter, in the absence of GVHD, CsA was tapered. Methylprednisolone 0.5 mg/kg/day i.v. was started on day ϩ7 and increased to 1.0 mg/kg/day on day ϩ14. Prednisone 1.25 mg/kg/day p.o. was substituted when oral intake became adequate. In the absence of GVHD, prednisone was tapered off between day ϩ28 and day ϩ56. Acute GVHD was treated with prednisone (0.5-2 mg/kg/day). Anti-thymocyte globulin (ATGAM, Pharmacia Upjohn, Kalamazoo, MI, USA) 40 mg/kg/day i.v. ϫ4 days was used for treatment of steroid-resistant GVHD. Chronic GVHD was treated at the discretion of the transplant physician. Recipients received G-CSF from day ϩ1 until ANC Ͼ1500/mm 3 for 3 days. Prophylactic gancyclovir was not given. Surveillance blood cultures for CMV (shell vial) were performed every other week from day ϩ21 until day ϩ150. CMV viremia was treated with gancyclovir 5 mg/kg once daily for 21 days.
PBSC collection
Donors received G-CSF 10 g/kg/day by subcutaneous injection for mobilization and underwent large volume apheresis as previously described. 6 Apheresis commenced on day 5 of G-CSF administration and continued until у2 ϫ 10 6 CD34 ϩ cells/kg recipient weight post processing were collected or until three aphereses had been performed.
CD34 selection procedure
BDS 60 is marketed for large volume separations as part of the 'DACS SC Kit'. For this study, BDS 60 was provided in sterile pre-filled 50 ml centrifuge tubes that contained a donut-shaped silicone insert. Mobilized PBSC were layered on to the top of the BDS 60 solution. The tubes were centrifuged at 850 g for 30 min at room temperature. After centrifugation high density cells sedimented in a pellet below the insert. The low density fraction, enriched for hematopoietic progenitors, was then recovered at the buffer-density solution interface and infused without further processing.
Immunophenotyping
Samples were obtained for flow cytometry from each apheresis product pre separation (pre-separation sample) and from the low density fraction post separation (post-separation sample). Lineage negative (lin Ϫ : negative for CD3, CD14, CD11b, CD19) CD34 ϩ cells were measured by FACS analysis by a modification of the technique of Roscoe et al, as previously described. 7 Lymphocyte subsets were enumerated by mixing samples containing 1 ϫ 10 6 leukocytes with the following four cocktails of fluorescentconjugated antibodies (Coulter-Immunotech, Fullerton, CA, USA): (1) CD3-FITC, CD4-PE, CD8-ECD and CD45-PECy5; (2) CD3-FITC, CD56-PE, CD19-ECD and CD45-PECy5; (3) CD2-FITC and CD45-PE-Cy5; (4) IgG1-FITC, IG1-PE, IgG1-ECD and CD45-PE-Cy5.
Cryopreserved pre-and post-separation samples of PBSC were thawed and viable (7AAD (Calbiochem, La Jolla, CA, USA) negative) cells were analyzed by FACS for total and CD80 ϩ dendritic cells (DC 
Cytokine assay
Cryopreserved aliquots of PBSC pre and post separation were thawed and viable cells were identified by the dye exclusion assay outlined above. A multi-probe ribonuclease protection assay (RiboQuant, Pharmingen, San Diego, CA, USA) was used to detect differences in expression of Th1 and Th2 cytokines, inflammatory cytokines and chemokines in the apheresis product. The quantity of protected RNA was determined using an imaging program with Gelbase/Gel-Blot Pro software (UVP Imaging, Upland, CA, USA). For quantitation, cytokine values were expressed as a ratio of the housekeeping gene L32 for each condition/gel lane.
Definitions and statistics
Neutrophil engraftment was defined as the first of 3 consecutive days with an ANC у500/mm 3 . The day of platelet engraftment was the day the platelet count reached у20 000/mm 3 without platelet transfusions for at least 7 days. Chimerism was assessed by VNTR performed on bone marrow between days 90 and 110 and on blood at 6 and 12 months. Acute GVHD was graded as per Glucksberg et al 8 and chronic GVHD as per Shulman et al. 9 Biopsies were not routinely performed, so the diagnosis of GVHD was based on clinical manifestations. For acute GVHD, patients who died before day ϩ21 without evi-
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dence of GVHD were not considered evaluable, while patients who died 21-100 days after transplant without GVHD were censored on the day of death. Patients surviving to day ϩ90 with evidence of engraftment were considered evaluable for chronic GVHD. Data analysis was performed using the StatView Program (Version 4.5; Abacus Concepts, Berkley, CA, USA).
Results
Patient characteristics
Between April and October 1997, 11 patients with advanced hematologic malignancies were enrolled (Table  1) . Median patient age was 45 years (range, 18-55) and median donor age was 44 (24-48) years. Five donor/recipient pairs were sex mismatched, with three male patients receiving grafts from female siblings. Nine patients and eight donors were CMV positive.
Results of density gradient separation
The composition of the pre-and post-separation specimens is shown in Table 2 . The mean number of CD34 ϩ /kg cells ϩ selection did not effect T cell activation markers CD25 and CD69. Viable DC from paired pre-and postseparation samples were available for eight donors. The device retained 53.9 Ϯ 22.2% of the DC. No difference was seen in expression of the activation marker CD80 between the pre-and post-separation specimens.
Outcome of transplant
All patients achieved neutrophil and platelet engraftment. The median day to achieve 500 neutrophils/mm 3 was 10 days (7-17) and platelets у20 000/mm 3 was 17 days (12) (13) (14) (15) (16) (17) (18) . Chimerism studies were performed by VNTR between days 90 and 110 in five patients (marrow four, blood one). All revealed complete donor engraftment (Ͻ1% recipient).
Grade II-IV acute GVHD occurred in seven patients (64%), at a median of 22 days with grade III-IV GVHD in five (45%) patients. Extensive chronic GVHD occurred in all five evaluable patients. At last follow-up, 9/11 (82%) patients have died at a median of 68 (38-245) days (Table  1) . Five (45%) died of transplant-related causes within 100 days of transplantation, four having active acute GVHD. Two patients, both with active chronic GVHD, died of CMV pneumonia after day ϩ100. Two patients died of recurrent disease. Two patients remain alive at 816 and 886 days post transplant, both with extensive chronic GVHD.
Cytokine expression
Pre-and post-separation samples were available for donors 2, 4, 5, 9, 10 and 11 while only post-separation samples were available for donors 1, 3 and 6. Expression of IL-8 and IFN-gamma mRNA was markedly increased in postseparation samples (Figure 1 ). In Table 3 , these two cytokines are expressed as a ratio of the housekeeping gene L32. Expression of IL-8 mRNA was increased several fold in post-separation samples from donors 2, 4, 5, 9 and 11. IFN-gamma expression was detected only after density gradient separation in donors 2, 4, 5 and 9. Unpaired postseparation samples from donors 1, 3 and 6, consistently expressed IL-8 and post-separation samples from donors 1 and 6 also expressed IFN-gamma (Table 3 ). The Th2 cytokines interleukin-4 and interleukin-10 were not detected in any of the samples tested. Furthermore, the assay did not detect significant expression of interleukins-5, 9, 13 or GM-CSF.
Discussion
Activated donor T cells are important mediators of GVHD. T cell depletion can be achieved by immunologic methods using murine monoclonal antibodies with specificity for T cell antigens or by physical methods including E-rosette depletion, soybean lectin agglutination, and counterflow centrifugal elutriation. [10] [11] [12] [13] [14] An alternative method of T cell depletion is CD34 ϩ selection. Most of the pilot trials studying CD34
ϩ selection have used one of two commercially available systems: (1) Ceprate SC biotin-avidin immunoadsorption columns (CellPro, Bothell, WA, USA) or (2) Isolex 300 system immunomagnetic columns (Baxter/Nexell, Munich, Germany). Table 4 summarizes the experience of authors studying CD34 ϩ selection of alloPBSC from HLA matched sibling donors as a method of T cell depletion. These devices have produced a 2.4 to 3.8 log reduction in the T cells. [15] [16] [17] [18] [19] [20] The clinical outcomes have been conflicting, with some authors reporting a reduction and others a higher than expected incidence of GVHD. More effective T cell depletion may be necessary to further reduce the risk of GVHD. This has been achieved by two-stage strategies which include CD34
ϩ selection along with a T cell antibody-based process. [21] [22] [23] [24] These techniques can produce nearly five log reduction of T cells in PBSC products.
The current report is the first to describe transplant outcome following CD34 ϩ enrichment of allogeneic PBSC using density gradient separation. We decided to study this device because processing is simple and rapid with the average processing time being 30 min compared to 2 to 4 h using immunoadsorption or immunomagnetic columns. Moreover, rapid and sustained hematopoietic reconstitution has been observed following autologous PBSC processed with this device. 5 The device effectively reduced the TNC of allogeneic PBSC products, which would facilitate a second processing step. As expected, the effectiveness of CD34 enrichment and of T cell depletion was much less than with immunoaffinity columns. However, the approximate one log reduction in T cells with this device, followed by immu-
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In the current trial we observed a relatively high risk of acute GVHD with 7/11 patients (64%) developing grade II-IV disease and 5/11 (45%) developing grade III-IV disease. This was associated with a high risk of death by day ϩ100 from transplant-related complications (5/11 patients; 45%). Therefore, rather than reducing the risk of acute GVHD, it appears that processing of PBSC with this device might increase the risk of acute GVHD. In a previous series of 50 similar patients with resistant hematologic malignancy who received G-CSF mobilized, allogeneic PBSC at our institution with identical GVHD prophylaxis, 34% of patients developed grade II-IV acute GVHD while 12% developed grade II-IV. The risk of grade III-IV acute GVHD among this cohort was significantly lower than that observed in the current trial (P = 0.02). However, inherent differences between these groups could also account for this difference.
Bensinger et al 20 and Finke et al 16 postulated that the increase in GVHD they observed in their series could possibly be related to a change in profile of lymphocyte subsets as a result of the CD34 ϩ selection procedure. In an attempt to explain how processing could increase the risk of acute GVHD, we examined the cytokine content of PBSC products in our cohort. We found that expression of IFNgamma and IL-8 was increased following processing. Interleukin-2 expression was not analyzed as the size of the transcript matched that of IL-8 on the assay. There are experimental and clinical data to suggest that both IFNgamma and IL-8 may be involved in the pathogenesis of GVHD. [25] [26] [27] [28] [29] One possible explanation for the increased expression of these cytokines is that processing caused activation of monocytes or dendritic cells. Alternatively, the device may have enriched the cell populations from which these cytokines are derived.
Bone Marrow Transplantation
This trial illustrates the potential adverse consequences of PBSC processing. These devices could have important effects on the activation status of T cells, monocytes and DC that are not reflected by quantification of T cells and CD34 ϩ cells. In future trials, a detailed analysis of these parameters and of the cytokine profiles of products pre and post processing might allow investigators to determine if a given procedure could have adverse consequences on the risk of GVHD after allogeneic PBSC transplant.
